Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia Orum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback